Pesquisar
Q32 Bio Inc
QTTBAdicionar à lista de desejos
15.140USD
-0.010-0.07%
Fechamento 07-27 16:00（ET）Cotações atrasadas em 15 min
186.29MValor de mercado
5.43P/L TTM
Mais detalhes de Q32 Bio Inc Empresa
Q32 Bio Inc. is a clinical-stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity in autoimmune and inflammatory diseases. It focuses on developing novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. Bempikibart (ADX-914), its advanced product candidate, is a fully human anti-interleukin-7 receptor alpha (IL-7Rα), an antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 (IL-7), and thymic stromal lymphopoietin (TSLP). It has completed two Phase IIa clinical trials evaluating bempikibart, SIGNAL-AA for the treatment of alopecia areata (AA), and SIGNAL-AD for the treatment of atopic dermatitis (AD). ADX-097, a Phase 2 asset and the lead product candidate from its complement inhibitor platform, is a humanized anti-C3d monoclonal antibody, fusion protein.
Informações de Q32 Bio Inc
Código da empresaQTTB
Nome da EmpresaQ32 Bio Inc
Data de listagemMar 28, 2018
CEOMorrison (Jodie Pope)
Número de funcionários42
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 28
Endereço830 Winter Street
CidadeWALTHAM
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02451
Telefone17819990232
Sitehttps://www.q32bio.com/
Código da empresaQTTB
Data de listagemMar 28, 2018
CEOMorrison (Jodie Pope)
Executivos da empresa Q32 Bio Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Dr. David S. Grayzel, M.D.
Dr. David S. Grayzel, M.D.
Independent Director
Independent Director
--
--
Mr. Diyong Xu
Mr. Diyong Xu
Independent Director
Independent Director
--
--
Ms. Kathleen D. Laporte
Ms. Kathleen D. Laporte
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Shelia M. Violette, Ph.D.
Dr. Shelia M. Violette, Ph.D.
Chief Scientific Officer, President of Research
Chief Scientific Officer, President of Research
73.10K
-25.65%
Dr. Isaac Manke
Dr. Isaac Manke
Independent Director
Independent Director
53.52K
--
Ms. Jodie Pope Morrison
Ms. Jodie Pope Morrison
Chief Executive Officer, Director
Chief Executive Officer, Director
23.10K
-285.66%
Mr. Lee H. Kalowski
Mr. Lee H. Kalowski
President, Chief Financial Officer
President, Chief Financial Officer
--
--
Dr. Adrien Sipos, M.D., Ph.D.
Dr. Adrien Sipos, M.D., Ph.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
Dr. Arthur O. Tzianabos, Ph.D.
Dr. Arthur O. Tzianabos, Ph.D.
Director
Director
--
--
Perguntas frequentes
Quem são os cinco principais acionistas de Q32 Bio Inc?
Os cinco principais acionistas de Q32 Bio Inc são: Dr. Shelia M. Violette, Ph.D.
Quantas instituições possuem ações da Q32 Bio Inc (QTTB)?
Em 2026Q1, 189 instituições possuíam ações da Q32 Bio Inc, com valor de mercado aproximado de 9.99M, representando 65.09% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -2048479.00.